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Abstract 
Restrictive cardiomyopathy (RCM) is a rare and distinct form of cardiomyopathy 
characterized by normal ventricular chamber dimensions, normal myocardial wall thickness, 
and preserved systolic function. The abnormal myocardium, however, demonstrates impaired 
relaxation. To date, dominant variants causing RCM have been reported in a small number of 
sarcomeric or cytoskeletal genes, but the genetic causes in a majority of cases remain 
unexplained especially in early childhood. Here, we describe two RCM families with 
childhood onset: one in a large family with a history of autosomal dominant RCM and the 
other a family with affected monozygotic, dichorionic/diamniotic twins.  Exome sequencing 
found a pathogenic filamin C (FLNC) variant in each: p.Pro2298Leu which segregates with 
disease in the large autosomal dominant RCM family, and p.Tyr2563Cys in both affected 
twins.  In vitro expression of both mutant proteins yielded aggregates of FLNC containing 
actin in C2C12 myoblast cells.  Recently, a number of variants in FLNC have been described 
that cause hypertrophic, dilated, and restrictive cardiomyopathies. Our data presented here 
provide further evidence for the role of FLNC in pediatric RCM, and suggest the need to 
include FLNC in genetic testing of cardiomyopathy patients including those with early ages 
of onset.  
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Introduction 
Cardiomyopathy (CM), a disease of heart muscle causing systolic and/or diastolic 
dysfunction, is a common cause of cardiac failure in children (Wilkinson, Westphal, Ross, 
Dauphin, & Lipshultz, 2015). Phenotypes include dilated (DCM), hypertrophic (HCM), 
restrictive (RCM), and arrhythmogenic forms (AVC), as well as left ventricular 
noncompaction (LVNC). RCM, the rarest of the cardiomyopathies, is defined as restrictive 
ventricular physiology in the presence of normal or reduced diastolic volumes, normal or 
reduced systolic volumes, and normal ventricular wall thickness (Vatta & Towbin, 2011). 
RCM accounts for up to 5% of cardiomyopathies in children, with the majority having no 
specific cause identified. The prognosis in children with RCM is poor—nearly 50% of 
patients die or undergo transplant within 3 years of diagnosis (Russo, 2005; Webber et al., 
2012). Familial RCM is reported in 30% of all cases and both autosomal recessive and 
autosomal dominant inheritance have been described (Denfield & Webber, 2010). In some 
families with autosomal dominant cardiomyopathy, both HCM and RCM have been 
identified, suggested shared genetic causes (Kaski, Biagini, Lorenzini, Rapezzi, & Elliott, 
2014). To date more than 100 genes have been implicated in various forms of CM (Tariq & 
Ware, 2014; Ware, 2015; Ware, 2017). These genes are involved in sarcomere, cytoskeleton, 
desmosome or mitochondria organization, metabolic processes, and other additional cellular 
functions (Harvey & Leinwand, 2011). 
 Despite progress in identifying various genetic causes for cardiomyopathies, little is 
known about the genetic etiology of RCM. To date, dominant pathogenic variants causing 
RCM have been reported in DES, ACTC1, TNNI3, TNNT2, TPM1, MYL3, MYL, MYPN, TTN, 
BAG3, FLNC, TTR and MYH7, but the majority of cases are considered idiopathic (Towbin, 
2014).  However, recent studies of idiopathic RCM cohorts tested using panels of 100-200 
cardiomyopathy-related genes show some success in identifying additional likely pathogenic 
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variants in genes including: DES, LAMP2, LMNA, BAG3, JUP, TTN, and others, with 50-
60% of patients having an identified potentially pathogenic variant (Gallego-Delgado et al., 
2016; Kostareva et al., 2016).  Although previous reports indicate yields of clinical genetic 
testing around 20% for RCM (Ackerman et al., 2011), data are limited. Identification of 
further genetic causes for RCM will be the first step for understanding the disease 
mechanisms, which may eventually lead to gene-specific diagnosis and potential therapy.   
Filamins are a group of large proteins important for structural integrity of cells that act 
by crosslinking actin filaments and anchoring membrane proteins to the cytoskeleton.  
Variants in FLNC have not only been reported in RCM patients but also in other 
cardiomyopathies and skeletal muscle diseases (Brodehl et al. 2016 and Valdés-Mas et al., 
2014; Vorgerd et al., 2005). In this study, we investigated two families with early onset 
RCM, identified FLNC variants using an exome sequencing (ES) approach, and performed in 
vitro functional analyses.  Using these approaches, we sought to expand the current spectrum 
of genetic variants associated with familial RCM. 
 
Methods 
Ascertainment of familial RCM and ethical considerations 
Patients underwent clinical evaluation by a pediatric geneticist and pediatric 
cardiologist at Cincinnati Children's Hospital Medical Center (CCHMC) or Children’s 
Hospital of Wisconsin. Patients and family members enrolled in a research study approved by 
the Institutional Review Boards (IRB) at CCHMC or Indiana University. Written informed 
consent for participation in this study, as well as publication of clinical data of the affected 
individuals was obtained from the families. All the methods applied in this study conformed 
to the Declaration of Helsinki (1964) of the World Medical Association concerning human 
material/data and experimentation. Genomic DNA of 6 individuals from Family 1 (Fig. 1A) 
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or 5 individuals from Family 2 (Fig. 2A) was extracted from whole peripheral blood 
leukocytes following a standard DNA extraction protocol (Promega, Madison, WI).   
 
Exome sequencing 
For Family 1, ES was performed on a research basis. Genomic DNA (2μg) from 
proband IV-2 (Fig.1A) was used for enrichment of human exonic sequences with the 
NimbleGen SeqCap EZ Human Exome v2.0 Library (2.1 million DNA probes; Roche 
NimbleGen, Inc, Madison, WI). Sequencing was performed with 50 bp paired-end reads 
using Illumina (San Diego, CA) GAII (v2 Chemistry) to a mean depth of approximately 56x. 
All sequence reads were mapped to the reference human genome (UCSC hg 19) using the 
Illumina Pipeline software version 1.5 featuring a gapped aligner (ELAND v2). Variant 
identification was performed using GATK (McKenna et al., 2010). Amino acid changes were 
identified by comparison to the UCSC RefSeq database track. A local CCHMC realignment 
tool was used to minimize the errors in SNP calling due to indels.  Exome data was initially 
screened for more than 300 genes known for cardiomyopathy or related phenotypes. Our 
filtering strategy removed previously reported variants in databases such as dbSNP (Sherry et 
al., 2001) and NHLBI Exome Sequencing Project (ESP) (http://evs.gs.washington.edu/EVS/), 
in addition to non-coding variants.  Remaining variants were tested for segregation with 
disease in the family, and further subject to pathogenicity prediction programs including: 
Polyphen-2, SIFT/PROVEAN, MutationTaster, and HOPE (Adzhubei et al., 2010; Choi, 
Sims, Murphy, Miller, & Chan, 2012; Schwarz, Cooper, Schuelke, & Seelow, 2014; 
Venselaar, Te Beek, Kuipers, Hekkelman, & Vriend, 2010).   
For Family 2, DNA samples were sent to the Advanced Genomics Laboratory at the 
Medical College of Wisconsin (MCW) for clinical ES of the parent and proband trio.  In 
brief, after enriching for coding exons with solution based hybridization, an Illumina HiSeq 
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2500 was used for sequencing.  Analysis of depth of coverage across exomes was performed 
with the GapMine software (MCW) with a minimum average depth of 85X.  Sequencing 
variants were interpreted with the Carpe Novo software package (MCW).  For this clinical 
pipeline, all identified variants were assessed for potential clinical significance.  In addition 
to filtering variants based on quality and allele frequency, Carpe Novo uses multiple 
algorithms and databases to assess variants including bioinformatics predictions on protein 
function and structure (Polyphen-2 and SIFT), evolutionary conservation at the affected 
residues, changes to known splice site donors or acceptors, and presence or absence of the 
variant in aggregate databases such as dbSNP, HGMD, or OMIM (Stenson et al., 2003; 
https://omim.org/).   
 
Variant screening and validation  
Primers (Supp. Table S1) were designed covering exonic regions containing potential 
candidate variants (FLNC, MYPN, and PKP2 in Family 1 and FLNC and SYNE2 in Family 2). 
PCR products were sequenced on an ABI (Foster City, CA) 3730XL Genetic Analyzer using 
BigDye Terminator (ABI, Foster City, CA). Sequence analysis was performed via FinchTV 
(https://www.geospiza.com). All positive findings were confirmed in a separate experiment 
using the original genomic DNA sample as template for new amplification and bi-directional 
sequencing reactions. The FLNC p.Pro2298Leu and FLNC p.Tyr2563Cys variants (Refseq 
NM_001458.4) were determined to be pathogenic according to the American College of 
Medical Genetics (ACMG) 2015 guidelines for variant interpretation (Richards et al., 2015) 
based on data presented here (see Results).  FLNC variants were submitted to ClinVar and 
have been assigned the following ClinVar accession numbers: SCV000787752 
(p.Pro22298Leu) and SCV000787753 (p.Tyr2563Cys). 
  
 This article is protected by copyright. All rights reserved. 
 
In silico protein homology modelling and viewing 
SWISS-MODEL (Biasini et al. 2014) modeled the Ig domains 20-21 of FLNC to 
depict amino acid position 2298.  The amino acid sequence of these domains was queried, 
and the template model most closely matching FLNC sequence was selected.  This model 
was based on the known crystal structure of FLNA’s Ig 20-21 domains (PDB 4P3W). A 
known crystal structure for FLNC Ig23 (PDB 2NQC) served as model to view amino acid 
position 2563. YASARA (Krieger & Vriend, 2014) was used to view both protein structures. 
 
Cell culture, plasmid transfection, and immunocytochemistry 
A human FLNC clone was purchased from Origene (Rockville, MD, catalog number 
RG212462) in a mammalian expression vector pCMV-AC-GFP. Mutagenesis was performed 
using primers designed (Supp. Table S2) for both the Q5 Site-Directed Mutagenesis Kit (New 
England Biolabs, Ipswich, MA) and the Infusion HD cloning kit (Clontech, Mountain View, 
CA).  Validations of full length FLNC pCMV-AC-GFP plasmids with wild type and mutant 
transcripts were carried out using primers listed in Supp. Table S3.  Both a standard calcium-
phosphate method and Neon electroporation (Invitrogen, Waltham, MA) were used for 
transfections. For calcium-phosphate transfections, C2C12 cells (American Type Culture 
Collection, Manassas, VA; CRL-1772) were cultured with 2 mL Dulbecco's Modified Eagle 
Medium (DMEM) containing 10% fetal bovine serum (Hyclone, Pittsburgh, PA) and 1% 
penicillin-streptomyocyin (Gibco, Waltham, MA) in a 2 well (4.0cm
2
) Lab-Tek chamber 
slide (Nunc, Rochester, NY) to reach 60% confluence on the day prior to transfection. To 
transfect, 5 µg of pCMV-AC-GFP FLNC wild type or mutant plasmids were combined with 8 
µl of 2M CaCl2.  This mix was added dropwise to 62.5 µl 2X HEPES buffered saline.  After 
30 minutes of precipitation, the combined solution was added to the culture media and 
incubated overnight.  After incubation, the transfection media was replaced with 2 mL fresh 
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media.  For Neon electroporation, 100,000 C2C12 cells and 0.75µg of plasmid DNA were 
used in each transfection using electroporation conditions of 1,650 volts, 10 ms pulse width, 
and pulse number 3. Cells were plated into two well chamber slides with 2mL of the above 
described DMEM. 
 Forty-eight to 72 hours post transfection, cells were prepared for 
immunocytochemistry.  All steps were carried out at room temperature.  Cells were washed 
with phosphate buffered saline (PBS) 3 times for 15 minutes, fixed with 4% 
paraformaldehyde for 30 minutes followed by repeated PBS washes, and then permeabilized 
with 1% Triton-X100 (Fisher Scientific, Waltham, MA) for 30 minutes.  Following 
permeabilization, blocking was carried out with 5% non-fat dried milk and 1% goat serum 
(Invitrogen, Waltham, MA) in 0.1% Tween-20 in PBS for 60 minutes. The following primary 
antibodies were incubated with cells for 3 hours: desmin (polyclonal rabbit α-mouse 1:200; 
Abcam, Cambridge, MA, ab8592) and FLNC (polyclonal goat α-mouse 1:500; Santa Cruz 
Biotechnology, Dallas, TX, sc-48496). Cells were washed with PBS and then incubated for 
60 minutes in the following secondary antibodies, all at 1:100 dilutions: goat α-rabbit Alexa 
Fluor 568 (ThermoFisher, Waltham, MA); donkey α-goat Alexa Fluor 594 (ThermoFisher); 
and F-actin was detected with the Phalloidin-conjugated Alexa Fluor 594 (ThermoFisher). 
The slides were then rinsed in PBS buffer for 15 minutes, mounted with Vectashield 
containing DAPI for nuclei counterstain (Vector Laboratories, Burlingame, CA), and 
examined under a fluorescence (Nikon Eclipse E400, Melville, NY) or confocal microscope 
(Carl Zeiss Apotome, Thornwood, NY). 
 
Pathology 
 Explanted heart tissue was fixed in 10% neutral buffered formalin for 24 hours at 
room temperature before embedding in paraffin (FFPE), sectioning, and staining with 
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hematoxylin and eosin (H&E) or trichrome.  Additionally, a portion of the ventricle was fixed 
in 3% glutaraldehyde in cacodylate buffer, and sectioned to one cubic millimeter for 




Family 1 showed a typical autosomal dominant mode of inheritance (Fig. 1A), and all 
affected members presented with isolated RCM diagnosed at early ages.  The family’s race is 
African American. The proband was given a diagnosis of RCM at age 8, and upon 
echocardiogram was found to have an indexed left atrial volume of 72 ml/m
2
, right atrial 
enlargement, and left ventricular diastolic dysfunction (Fig. 1B).  Cardiac catheterization 
confirmed the diagnosis of RCM (Rindler, Hinton, Salomonis, & Ware, 2017). He underwent 
transplant at age 11.  The patient’s sister was followed by echocardiography due to the family 
history of RCM and first showed evidence of biatrial enlargement at age 4. She underwent 
cardiac catheterization and was given a diagnosis of RCM at age 5 and was listed for 
transplant which occurred at age 7.  The paternal aunt was diagnosed with RCM at age 3 and 
the paternal half-sister was diagnosed under the age of 10. All of the affected individuals 
presented disease symptoms without evidence of myopathy or other extra-cardiac findings.  
Clinical genetic testing for 10 genes (MYBPC3, MYH7, ACTC1, DES, MYL2, MYL3, TNNI3, 
TNNT2, TPM1, and EMD) was performed as part of the clinical diagnostic evaluation and no 
sequence variants were reported by the clinical testing laboratory. 
The proband in Family 2, is a 1 year old Caucasian female who presented with acute 
onset of unilateral weakness and was found to have a left sided thromboembolic middle 
cerebral artery stroke. Evaluation for etiology revealed classic phenotypic changes consistent 
with RCM including normal ventricular dimension and systolic function with massively 
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dilated atria (Fig. 2B).  Of note, the child had an echocardiogram in the perinatal period that 
was normal aside from a small muscular ventral septal defect with restrictive left to right 
shunt.  Due to elevated pulmonary vascular resistance, she was listed for heart transplant 
shortly after diagnosis and successfully transplanted months later. Family echocardiographic 
screening revealed her twin sister had similar phenotypic findings of RCM, while her brother, 
mother, and father were all unaffected (Fig. 2A).   The twin sister progressed over months to 
require heart transplant listing and was successfully transplanted as well.  Of note, each twin 
also presented with extra-cardiac phenotypes at the time of RCM diagnosis, including 
unspecified developmental delay, hypotonia, dysmorphic facial features, and clasped thumbs.  
Further, they each demonstrated kidney dysfunction of unclear etiology by three years of age, 
post heart transplant. 
 
Pathology 
 Explanted heart tissue from the proband in Family 1 was processed for both histology 
and transmission electron microscopy (EM).  H&E staining revealed some myocyte 
hypertrophy nuclear size changes, and occasionally central nuclei (Fig. 3A), whereas 
trichrome staining at lower magnification showed some differences in fiber sizes, and lacy 
interstitial fibrosis (Fig. 3B).  EM of the explanted tissue showed essentially normal 
ultrastructure: there were no lipid or glycogen deposits. Relevant for FLNC-related 
myopathies, there were no inclusions or depositions observed. Mitochondrial organization 
and sarcomere structure (Fig. 3C-D) appeared normal and regular with no disarray, as is 
frequently seen in patients with MYH7 or MYBPC3 variants (Wessel et al., 2015; Witjas-
Paalberends et al., 2013).  The proband and twin sister from Family 2 also had explanted 
heart tissue processed for EM. Both proband (Fig. 3E) and sister (Fig. 3F) also demonstrate 
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regular sarcomeric structure, with no evidence of myofibril degeneration or signs of irregular 
mitochondria organization, aggregates, or depositions. 
 
Exome analysis 
After variant filtering, we identified 3 candidate variants in the proband in Family 1. 
These included variants in MYPN (p.Ser1282Arg), PKP2 (p.Val798Ile), and FLNC 
(p.Pro2298Leu). These sequence changes were tested in additional family members and only 
the FLNC missense variant p.Pro2298Leu (c.6893C>T; NM_001458.4) co-segregated with 
the RCM phenotype in the family, supporting a dominant mode of inheritance (Fig. 1C).  The 
p.Pro2298Leu variant is located in exon 41 of FLNC and falls in the immunoglobulin-like 
(Ig) 20 (a.a. 2244-2306) domain of the protein.   This variant is not present in the Exome 
Aggregation Consortium (ExAC) (Lek et al., 2016).  Additionally, the variant is located 
outside the region of homology transcribed FLNC shares with the identified FLNC-like 
pseudogene (Odgerel, van der Ven, Fürst, & Goldfarb, 2010).   
Clinical ES of the trio and filtering strategies were used to identify potential disease 
causing variants in the proband of Family 2.  Ultimately, three variants in two genes, FLNC 
and SYNE2 (a gene associated with autosomal dominant Emery-Dreifuss muscular 
dystrophy), were filtered as being potentially clinically important.  Each SYNE2 variant 
(p.Val1688Ile and p.Lys4931Arg) was inherited from a healthy parent (Supp. Figure S1).  
Additionally, these variants were predicted to be benign by pathogenicity prediction, found in 
variant databases such as ExAC and dbSNP, and neither twin presented classical signs of 
Emery-Dreifuss by two years of age.  The identified FLNC variant p.Tyr2563Cys 
(c.7688A>G; NM_001458.4) was present in both twins and absent in unaffected parents and 
sibling (Fig. 2C) indicating it was de novo.  It was not found in ExAC or dbSNP, is located in 
Ig domain 23, and was confirmed to be in the functional FLNC gene and not its pseudogene. 
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In silico pathogenicity prediction 
Both the autosomal dominant p.Pro2298Leu and de novo p.Tyr2563Cys variants in 
FLNC were unanimously predicted to be pathogenic using bioinformatic programs Polyphen-
2, SIFT/PROVEAN, and Mutation Taster (Supp. Table S4).  Further, the program HOPE 
(Venselaar, Te Beek, Kuipers, Hekkelman, & Vriend, 2010) was used to discover and 
analyze potential changes to protein structure resulting from each variant (Supp. Table S4).  
Proline at position 2298 of FLNC, as well as its respective triplet codon (CCC) in the gene, 
are evolutionary conserved across species suggesting an important role of this residue in 
protein function (Fig. 1D). Prolines are known to be very rigid and therefore induce a special 
backbone conformation which might be required at this position.  All filamins consist of an 
N-terminus actin-binding domain followed by 24 antiparallel β-sheet repeats (called filamin 
or Ig-like domains), the 24
th
 of which is responsible for filamin homo-dimerization at the C 
terminus (Stossel et al., 2001).  These 24 Ig filamin repeats of the FLNC protein primarily 
form a secondary structure of beta strands, as seen in a model of Ig domains 20-21 (Fig. 4A) 
(Sjekloća et al., 2007).  The side chain of proline will typically disrupt β-strands due to its 
unique ring structure (Li, Goto, Williams, & Deber, 1996), and indeed proline 2298 falls in a 
loop between two such strands (Fig. 4B). The change to leucine at this position could disturb 
this special conformation and lead to protein aggregates. β-rich proteins like FLNC are prone 
to aggregation, and a leucine substitution could have a higher propensity to form hydrogen 
bonds between other nearby β-strands which could potentially disrupt protein folding and 
lead to aggregate formation (Hecht, 1994; Venselaar, Te Beek, Kuipers, Hekkelman, & 
Vriend, 2010). 
Tyrosine at position 2563 is also evolutionarily conserved across species (Fig. 2D), 
and is located at the end of a β-strand (Fig. 4C-D).  The mutant cysteine residue is less 
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hydrophobic and smaller than the wild type tyrosine, and due to its size is predicted to cause 
an empty space in the protein.  The difference in hydrophobicity is also predicted to lead to a 
loss of hydrogen bonds at the core, which could disturb proper protein folding (Venselaar, Te 
Beek, Kuipers, Hekkelman, & Vriend, 2010).  In addition to changes to hydrophobicity, the 
specific tyrosine to cysteine substitution may also be contributing to p.Tyr2563Cys protein 
aggregation (shown in results below).  Substitution of tyrosine and cysteine at key resides of 
the human α-synuclein protein has been shown to cause accelerated protein aggregation in 
vitro, likely due to the increased ability for cysteine residues to cross-link and form stable 
dimers, which could be more prone to polymerization and aggregation (Zhou  & Freed, 
2004).  
 
In vitro analysis of FLNC mutants  
Previous studies of filaminopathies have shown evidence of mutant FLNC 
intracellular protein aggregation in both immuno-histological sections of patient muscle and 
in in vitro transfection of mutant FLNC constructs (Kley et al., 2007; Valdés-Mas et al., 
2014; Vorgerd et al., 2005).  These aggregates often contain additional Z-disk associated 
proteins such as desmin, a hallmark of myofibrillar myopathy.  In order to determine whether 
the p.Pro2298Leu and p.Tyr2563Cys variants would also lead to intracellular protein 
aggregation, full-length wild type and mutant FLNC-GFP constructs were transiently 
expressed in C2C12 mouse myoblasts.   
Cells expressing the wild type FLNC construct exhibited diffuse homogeneous 
expression of the protein (Fig. 5B and 5N), whereas the p.Pro2298Leu construct yielded 
aggregates (Fig. 5F and 5R), often near the nucleus.  Additionally, the number of cells 
expressing p.Pro2298Leu mutant protein appeared considerably lower than those expressing 
the wild type FLNC construct.  Cells expressing the mutant p.Tyr2563Cys construct also 
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demonstrated areas of FLNC aggregation (Fig. 5J and 5V), though these aggregates were 
punctate and varied in size from small to intermediate.  Unlike the results seen with the 
p.Pro2298Leu construct, the diffuse FLNC expression was not lost in these cells; rather, the 
p.Tyr2563C aggregates appeared to be randomly distributed throughout otherwise normal 
protein expression.  The pattern of aggregation observed for our p.Tyr2563Cys construct 
most closely mirrors what has been observed in cells transfected with FLNC variants causing 
distal myopathy (Duff et al., 2011).  Additionally, unlike FLNC variants associated with 
myofibrillar myopathy, we did not observe the presence of desmin aggregation with mutant 
FLNC aggregates (Fig. 5S and 5W) or endogenous Flnc co-localizing to exogenous FLNC 
aggregates (Fig. 5G and 5K).   
Given the importance of FLNC as an actin-binding protein, and in vitro data 
suggesting that FLNC variants may cause actin-aggregation (Kley et al., 2012), we transiently 
transfected p.Pro2298Leu and p.Tyr2563Cys constructs into C2C12 cells and stained for F-
actin.  As previously seen, the wild type FLNC construct showed diffuse cellular expression 
(Fig. 6A-D).  The p.Pro2298Leu mutant again resulted in intracellular FLNC aggregates, but 
these cells also had actin aggregates which appear to co-localize with mutant protein (Fig. 
6E-H).  Taken together, these results suggest the p.Pro2298Leu variant results in an unstable, 
mutant protein which is prone to aggregation and may contribute to the overall weakening of 
myofibers as evidenced by actin aggregation.  Cells transfected with the p.Tyr2563Cys 
construct also contained aggregates of both FLNC and F-actin (Fig. 6I-L), which again 
appeared more punctate, and varied in size.  Overall, these data suggest the p.Tyr2563Cys is 
a potentially damaging variant, as it results in aggregates containing both FLNC and F-actin.   
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Discussion 
In this study, we described two families with novel FLNC variants as disease causing 
for RCM: one, in a large family with autosomal dominant inheritance, and the other in a set 
of monozygotic, dichorionic/diamniotic twins with extra-cardiac features and a de novo 
variant.  According to the 2015 ACMG variant interpretation guidelines, both variants can be 
classified as pathogenic. Our evidence to support pathogenicity for p.Pro2298Leu includes: 
damaging in vitro functional study (PS3); variant found in a mutation hot-spot of 
cardiomyopathy variants (PM1—see Table 1); variant absent from control databases (PM2); 
variant segregates with disease in family (PP1); computational evidence supports deleterious 
effect (PP3); and the patient and family have a disease consistent with a single genetic 
etiology (PP4).  p.Tyr2563Cys is also pathogenic based on the following criteria listed above: 
PS3, PM1, PM2, PP3, and also a second strong level of evidence; the variant is de novo with 
maternity and paternity confirmed (PS2).  Additionally we do not believe the twins’ 
compound heterozygous SYNE2 variants explain RCM, although it remains unclear whether 
they might contribute to some extra-cardiac features. In sum, we have discovered two new 
pathogenic FLNC variants causing an RCM phenotype. 
 FLNC is a Z-disk protein which binds to myozenin-1 and myotilin, and its expression 
is largely restricted to skeletal and cardiac muscles (Linnemann et al., 2010; van der Ven et 
al., 2006).  In addition, FLNC interacts with the components of dystrophin-dystroglycan 
complex at the sarcolemma, thus acting as a scaffolding protein (Thompson et al., 2000). 
Altogether, Filamins interact with more than 90 cellular proteins with diverse functions 
including cell to cell and cell matrix connections, mechanoprotection, and various signaling 
networks (Feng & Walsh, 2004; Razinia, Mäkelä, Ylänne, & Calderwood, 2012). Recent data 
by Leber et al. (2016) show evidence of FLNC as a key early protein involved in myofibril 
repair for both skeletal and cardiac muscle cells. Their work suggests FLNC may be more of 
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a mobile signaling hub, rather than a largely structural and static protein (Leber et al., 2016).   
The early onset of RCM in the presented families suggests the importance of FLNC 
expression and its role in heart function.  
FLNC variants are a recently recognized cause of phenotypically distinct 
cardiomyopathies including HCM, DCM, and RCM (Begay et al., 2016; Brodehl et al., 2016; 
Valdés-Mas et al., 2014). FLNC-related cardiomyopathies present a challenge in 
extrapolating genotype-phenotype correlations based on variant position (Table 1).  Valdés-
Mas et al., identified 8 HCM variants of which 2 are located in the actin binding domain, 
while the other 6 are distributed throughout the 24 filamin Ig domains. Interestingly, 5 of 
these 6 variants are located in C-terminal half of the protein and 4 are notably clustered in 
filamin repeats 18-22.  A larger cohort of HCM patients sequenced by the same group 
identified additional candidate FLNC variants as potentially disease causing, most of which 
fell in the latter half of the protein (Gómez et al., 2017).  Of interest, one likely pathogenic 
variant identified by Gómez et al. was at the same residue position (p.Pro2298Ser) as the 
variant reported here in family 1 (p.Pro2298Leu).  The pattern of HCM variants falling in the 
C-terminal half of the protein is also seen with RCM variants: the two we report here fall in 
filamin repeats 20 and 23, a neighboring RCM variant to p.Pro2298Leu (p.Val2297Met) was 
recently reported by Tucker et al., 2017, and variants published by Brodehl et al. (2016) 
localize in repeats 14 and 19. 
  FLNC variants causing DCM have the most direct evidence of a genotype-phenotype 
relationship. Of the 8 previously reported DCM variants, 5 are splice site variants (Begay et 
al., 2016; Begay et al., 2018; Golbus et al., 2014), while 3 are nonsense variants resulting in 
an early protein truncation (Begay et al., 2018; Reinstein et al., 2016).  Genetic screening of 
large DCM patient cohorts revealed an association with truncating FLNC variants (stop 
codons, frameshifts, and splice site variants), strongly suggesting an overlap between 
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mutation mechanisms and patient phenotype (Janin et al., 2017; Ortiz-Genga et al., 2016).  
Until recently, skeletal myopathy and cardiomyopathy-causing FLNC variants have been 
reported to cause isolated phenotypes in their respective tissues. Interestingly, however, a 
new publication has described disease-causing FLNC variants leading to both early-onset 
RCM and the skeletal muscle phenotypes congenital myopathy and clasped thumbs (Kiselev 
et al., 2018).  The patients described here showed no evidence of myopathy on repeated 
exams although the twins did exhibit hypotonia.  In light of the report by Kiselev et al. 
(2018), it is possible the p.Tyr2563Cys variant could be contributing to the twins’ observed 
skeletal muscle phenotypes (hyoptonia and clasped thumbs), although this variant is not near 
the two variants Kiselev et al. found (p.Ala1183Leu and p.Ala1186Val).  However, we do not 
believe the twins’ other syndromic-like phenotypes, such as developmental delay and 
dysmorphic facial features, can likely be explained by a FLNC variant alone, and those hint at 
the possibility of a second underlying disorder.  Additional functional studies will be 
necessary to determine the FLNC variant-specific effects resulting in isolated skeletal or heart 
muscle disease, or those which affect both tissues. In addition, mechanisms to explain the 
divergent cardiac phenotypes resulting from distinct FLNC variants remain to be elucidated.  
Functional and structural analyses suggest that FLNC-mutants recruit FLNC-
associated proteins to form aggregates, leading to destabilization of muscle tissue (Lowe et 
al., 2007; Luan, Hong, Zhang, Wang, & Yuan, 2010). Abnormal accumulations of FLNC 
deposits in patients’ muscle tissues have been reported in a number of neuromuscular 
diseases (Bōnnemann et al., 2003; Sewry et al., 2002; Thompson et al., 2000). In vitro 
analyses for mutant FLNC p.Pro2298Leu revealed formation of perinuclear intracellular 
aggregates, while p.Tyr2563Cys expressing cells also formed point aggregates containing 
FLNC and F-actin, confirming the likely pathogenicity of these variants. Of note, similar 
experiments for HCM, DCM, and RCM FLNC mutants also resulted in aggregations of 
 This article is protected by copyright. All rights reserved. 
 
mutant protein, many of which shared a similar pattern of aggregate expression around the 
nucleus (Brodehl et al. 2016, Reinstein et al., 2016; Valdés-Mas et al., 2014).  The exact 
mechanism for this aggregate-based pathogenicity is unknown, but this could be an error in 
ubiquitination and lysosomal-dependent degradation of mutant FLNC as well as of other 
members of filamins.  
Changes in filamin structure initiate the binding of the co-chaperone BAG3 as well as 
the ubiquitin ligase CHIP. CHIP ubiquitinates BAG3 and filamin leading to autophagy by 
p62 pathway (Arndt et al., 2010).  Recent data suggest aggregates produced by the filamin C 
p.Trp2710X MFM variant in zebrafish were unable to be cleared properly by BAG3 and the 
chaperone assisted selective autophagy pathway (Ruparelia, Oorschot, Ramm, & Bryson-
Richardson, 2016).  Additionally, they noted the presence of BAG3 at these aggregates 
hindered alternative pathways that might have been able to remove them.  Further studies of 
FLNC-aggregates produced by a wide range of variants are needed in order to elucidate the 
mechanisms by which these aggregates persist, and to develop potential methods to clear 
them. 
In summary, we identified two novel FLNC missense variants causing a distinct RCM 
phenotype in two families, and further demonstrated these variants lead to protein 
localization defects in vitro.  This study provides new variants and additional evidence for the 
wide spectrum of currently known FLNC variants, and bolsters support for the inclusion of 
FLNC in genetic testing of cardiomyopathy patients. 
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Figure Legends 
Figure 1: Family 1 phenotypic and genetic evaluation. (A) Four-generation pedigree of 
Family 1 with autosomal dominant restrictive cardiomyopathy (RCM). DNA samples were 
available from individuals with a star. Proband IV-2 was analyzed by exome sequencing. (B) 
Echocardiogram image showing enlarged atria in the proband. (C) Sanger confirmation of 
FLNC variant (p.Pro2298Leu) in the affected proband and wild type allele in the unaffected 
mother (III-5). Arrows show the point of mutation (C>T). (D) Partial sequences of FLNC 
protein highlighting cross species conservation of proline residue at amino acid 2298. 
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 Figure 2: Family 2 phenotypic and genetic evaluation. (A) Four-generation pedigree of 
Family 2 with de novo RCM in twin sisters. DNA samples were available from individuals 
with a star sign. Proband IV-7 was analyzed by exome sequencing. (B) Echocardiogram 
image showing dilation of both atria in the proband. (C) Sanger confirmation of FLNC 
variant (p.Tyr2563Cys) in one twin and wild type allele in unaffected father and mother. 
Arrows show the point of mutation (A>G). (D) Partial sequences of FLNC protein 
highlighting cross species conservation of tyrosine residue at amino acid 2563. 
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Figure 3: Pathological analysis of explanted heart tissue.  (A) Hematoxylin and eosin (H&E) 
staining of ventricle from the proband of Family 1, 40X magnification.  Black arrowheads 
denote examples of myocyte hypertrophy (B) Trichrome staining of ventricle from the 
proband of Family 1, 10X.  Black arrows show examples of interstitial fibrosis. (C) Electron 
microscopy showing a magnified example of sarcomere structure in proband of Family 1, and 
(D) striated (z-lines) muscle cell structure with interspersed mitochondria.  Panels E 
(proband) and F (twin sister) show representative EM images of sarcomeric structure from 
explanted heart tissues of Family 2.   
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Figure 4: Protein modelling of FLNC variants. (A) An overview of FLNC protein domains 
Ig20-21 based on homology modeling using the known FLNA crystal structure of Ig20-21 
(PDB 4P3W).  P2298 falls in a ―break‖ between two beta-strands, and is marked with an 
arrow. (B) A zoomed in view of the P2298 residue falling between beta-strands (colored 
yellow).  Proline side chain is also depicted, which likely leads to disruption of strands. (C) 
An overview of FLNC protein domain Ig23 based on the available crystal structure (PDB 
2NQC).  Y2563 is located at the end of a beta strand, and is marked with an arrow. (D) A 
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Figure 5: Expression of wild type and mutant FLNC in transiently transfected C2C12 cells.  
(A-L)  Fluorescence microscopy images of C2C12 cells transfected with full-length wild type 
(A-D), p.Pro2298Leu (E-H), and p.Tyr2563Cys (I-L) FLNC constructs and counterstained 
for endogenous mouse Flnc (C, G, and K).  (M-X) Fluorescence microscopy images of 
C2C12 cells transfected with wild-type (M-P), p.Pro2298Leu (Q-T), and p.Tyr2563Cys (U-
X) FLNC constructs and counterstained for endogenous desmin (O, S, and W).  All images 
have scale bars of 10µm, and 40X magnification.  Arrows denote areas of mutant FLNC 
aggregation (panels F, H, J, L, R, T, V, and X).   
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Figure 6: Actin aggregation in C2C12 cells transiently transfected with mutant FLNC.  (A-
D) Fluorescence microscopy images of C2C12 cells expressing the transfected wild type 
FLNC-construct.  Scale bars 10µm, 40X magnification.  (E-H)  Confocal microscopy images 
of C2C12 cells expressing the mutant Pro2298Leu protein.  Scale bars 10µm, 40X. (I-L) 
Cells expressing the mutant Tyr2563Cys protein.  Scale bars 10µm, 40X.  (A, E, I) Panels 
depict DAPI nuclear staining, (B, F, J) FLNC-GFP, (C, G, K) Phalloidin staining F-actin, 
(D, H, L) and a merged image of all three channels.  Arrows denote areas of mutant FLNC 
and actin aggregation.   
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Table 1: Reported FLNC variants causing skeletal myopathy or cardiomyopathies. HCM = 
hypertrophic cardiomyopathy, DCM = dilated cardiomyopathy, RCM = restrictive 
cardiomyopathy, LV = left ventricle, AVC = Arrhythmogenic ventricular cardiomyopathy.  
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9 patients 
No Australian Duff et al., 
2011 
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DCM N/A Begay et al., 
2018 
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